April 17, 2023
Study Uncovers Why Some Lung Cancers Avoid Immunotherapy
New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.
Technology Networks
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
April 17, 2023
New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.
Technology Networks
April 17, 2023
Pre-surgical immunotherapy along with post-surgical immunotherapy significantly improved survival compared to chemotherapy alone for patients with operable non-small cell lung cancer.
News-Medical.Net
April 17, 2023
The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.
Cure Today
April 14, 2023
The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.
PMLiVE
April 14, 2023
Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.
AJMC
April 14, 2023
The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.
Cure Today
March 9, 2023
Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.
Cure Today
March 9, 2023
Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.
Healio
February 25, 2023
Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.
Daily Bruin
February 8, 2023
Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.
Weill Cornell Medicine
February 1, 2023
New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.
Yale School of Medicine
January 20, 2023
The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.
Medpage Today
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.